nach oben

Erschienen in:

Open Access 01.12.2020 | Review

Cognitive impact of COVID-19: looking beyond the short term

verfasst von: Scott Miners, Patrick G. Kehoe, Seth Love

Erschienen in: Alzheimer's Research & Therapy | Ausgabe 1/2020

Abstract

COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show evidence of central nervous system (CNS) damage, predominantly ischaemic, in some cases haemorrhagic and occasionally encephalitic. It is unclear how much of the ischaemic damage is mediated by direct or inflammatory effects of virus on the CNS vasculature and how much is secondary to extracranial cardiorespiratory disease. Limited data suggest that the causative SARS-CoV-2 virus may enter the CNS via the nasal mucosa and olfactory fibres, or by haematogenous spread, and is capable of infecting endothelial cells, pericytes and probably neurons. Extracranially, SARS-CoV-2 targets endothelial cells and pericytes, causing endothelial cell dysfunction, vascular leakage and immune activation, sometimes leading to disseminated intravascular coagulation. It remains to be confirmed whether endothelial cells and pericytes in the cerebral vasculature are similarly targeted. Several aspects of COVID-19 are likely to impact on cognition. Cerebral white matter is particularly vulnerable to ischaemic damage in COVID-19 and is also critically important for cognitive function. There is accumulating evidence that cerebral hypoperfusion accelerates amyloid-β (Aβ) accumulation and is linked to tau and TDP-43 pathology, and by inducing phosphorylation of α-synuclein at serine-129, ischaemia may also increase the risk of development of Lewy body disease. Current therapies for COVID-19 are understandably focused on supporting respiratory function, preventing thrombosis and reducing immune activation. Since angiotensin-converting enzyme (ACE)-2 is a receptor for SARS-CoV-2, and ACE inhibitors and angiotensin receptor blockers are predicted to increase ACE-2 expression, it was initially feared that their use might exacerbate COVID-19. Recent meta-analyses have instead suggested that these medications are protective. This is perhaps because SARS-CoV-2 entry may deplete ACE-2, tipping the balance towards angiotensin II-ACE-1-mediated classical RAS activation: exacerbating hypoperfusion and promoting inflammation. It may be relevant that APOE ε4 individuals, who seem to be at increased risk of COVID-19, also have lowest ACE-2 activity. COVID-19 is likely to leave an unexpected legacy of long-term neurological complications in a significant number of survivors. Cognitive follow-up of COVID-19 patients will be important, especially in patients who develop cerebrovascular and neurological complications during the acute illness.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Aβ

Amyloid-β

ACE

Angiotensin-converting enzyme

ACE-I

Angiotensin-converting enzyme-1 inhibitor

Alzheimer’s disease

ApoE

Apolipoprotein E

APP

Amyloid-β precursor protein

Ang-II

Angiotensin II

ARB

Angiotensin receptor blocker

ARDS

Acute respiratory distress syndrome

AT1R

Angiotensin type 1 receptor

BBB

Blood-brain barrier

BSG

Basigin

CNS

Central nervous system

CVD

Cerebrovascular disease

DIC

Disseminated intravascular coagulation

IFN-β

Interferon-β

ICH

Intracerebral haemorrhage

Interleukin

LRP-1

Low-density lipoprotein receptor-related protein 1

MMP

Matrix metalloproteinase

MER

Middle East respiratory syndrome

NRP1

Neuropilin

PDGFRβ

Platelet-derived growth factor-β

PET

Positron emission tomography

RAS

Renin-angiotensin system

SARS

Severe acute respiratory syndrome

SARS-CoV-2

Severe acute respiratory syndrome coronavirus-2

SVD

Small vessel disease

TLR4

Toll-like receptor 4

Background

COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is primarily a respiratory disease but has the capacity to damage other organs including the brain. Similarly to the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MER) viruses [1‐3], SARS-CoV-2 targets the brain (reviewed [4]) and a growing number of case reports and cohort studies indicate significant neurological disturbance in COVID-19 patients (reviewed [5]). Central nervous system (CNS) involvement including non-specific encephalopathy (headache, confusion, and disorientation) was first documented in 53/214 (25%) hospitalised patients in Wuhan, China [6]. More recent studies in Europe have reported higher rates of CNS involvement: 69% of 58 hospitalised patients in a French Study [7], and 31% of 125 cases with altered mental state, including psychosis and neurocognitive changes, in a recent UK survey [8]. A recent report described a ‘dysexecutive syndrome consisting of inattention, disorientation, or poorly organised movements in response to command’ in 33% of 43 patients discharged from hospital [7]. Moreover, neuroradiological evidence of microstructural damage and disruption of functional brain integrity at 3-month follow-up in recovered COVID-19 patients [9] indicates potential long-term neurological consequences in severely affected COVID-19 patients (reviewed [10]). Acute cerebrovascular disease (CVD), typically presenting as ischaemic stroke but occasionally as intracerebral haemorrhage (ICH), has emerged as an important clinical feature in COVID-19 (reviewed in [5]). There have also been multiple case reports of encephalitis with brain-stem involvement (reviewed in [5]). CNS involvement with neurological presentation is more frequent in older and more severely ill COVID-19 patients [6]. Based on the minimum prevalence of neurological complications in SARS and MERS, Ellul et al. [5] estimated that of the reported 4.8 million COVID-19 cases at the time, 1805–9671 had developed CNS complications.

Human coronaviruses are known to target the CNS and cause damage by direct neurotoxicity or activation of the host immune response [1]. The propensity of SARS-CoV-2 to cause cerebral vascular injury greatly increases the risk of chronic brain damage, not only because of the cumulative destructive effect of multifocal cerebral ischaemia or haemorrhage, but potentially also through chronic post-infective complications of CVD, including endothelial and blood-brain barrier (BBB) dysfunction and upregulation of pro-inflammatory cytokines within the brain [11]. Long-term cognitive decline and neurodegeneration, with associated hippocampal atrophy [12], were previously reported to complicate systemic inflammation associated with severe sepsis [13, 14]. Acute respiratory distress syndrome (ARDS), a common clinical presentation in COVID-19 patients, is also associated with cognitive decline and neurodegeneration [15, 16]. Long-term follow-up of COVID-19 patients that includes detailed cognitive assessment will be important, to determine the extent and prevalence of long-term neurological and psychiatric consequences of COVID-19 [17], especially in patients who develop cerebrovascular and neurological complications during the acute illness.

In this review, we discuss the pathophysiological processes and risk factors shared by COVID-19 and dementia, focussing particularly on the role of cerebrovascular disease and the involvement of the renin-angiotensin system (RAS) (Table 1). We consider whether SARS-CoV-2 infection may increase the risk of later developing dementia, particularly in people with underlying cerebrovascular disease and high-risk co-morbidities, such as diabetes and hypertension.

Table 1

Pathophysiological processes contributing to increased risk of chronic neurological disease, including dementia, in COVID-19 patients

	References
1. Hypoxia and cerebral hypoperfusion secondary to cardiorespiratory disease	[25, 26]
- Hypoxic-ischaemic brain injury, diffuse white matter damage
2. Coagulopathy, with thrombotic occlusion of cerebral blood vessels	[22]
- Cerebral artery thrombosis, disseminated intravascular coagulation
3. Cerebral microvascular damage and dysfunction	[23, 24]
- Endotheliitis, pericyte damage, BBB leakiness, neurovascular dysfunction, impaired autoregulation, impaired vascular/para-vascular drainage
4. Dysregulation of renin-angiotensin system	[125‐127, 160, 161]
- Loss of regulatory RAS and overactivity of classical RAS signalling
5. SARS-CoV-2 encephalitis / post-infective encephalitis (rare)	[27, 28, 38], reviewed in [5]
- CNS viral neuroinvasion via olfactory nerve fibres or vasculature/post-infective immune injury to CNS

Cerebral vascular disease (CVD) is common in severe COVID-19

Unlike in SARS and MERS, COVID-19 patients are at substantial risk of developing acute CVD. Studies to date indicate that CVD has affected 2–6% of hospitalised patients with COVID-19 (reviewed in [5]). In a Spanish cohort, 23 of 1683 patients (1.4%) developed CVD, with cerebral ischaemia accounting for 74% and ICH for 23% of the 23 cases [18]. Amongst COVID-19 patients with neurological complications, the reported incidence of CVD is much higher. Acute CVD was diagnosed in 77% of 56 patients admitted to a neurology ward in Italy [19]. In a recent UK-wide survey of 153 COVID-19 cases with neurological and/or psychiatric disturbance, most patients (62% of 125), for whom a full clinical dataset was available, had had a cerebrovascular event, compared to 31% with encephalopathy; of those with CVD, 74% had presented with ischaemic stroke, 12% with ICH, and 1% with CNS vasculitis [8]. A common theme across most of these studies is the predominance of CVD in older patients in association with more severe disease, and in those with co-morbidities, including hypertension, diabetes and underlying cerebrovascular disease [20]. However, large-vessel stroke has also been reported in younger adults with COVID-19 [21].

The pathophysiology of CVD in COVID-19 has yet to be fully determined (Fig. 1). Inflammation-induced disseminated intravascular coagulation (DIC), often complicated by pulmonary embolism, has been documented in a high proportion of patients with neurovascular complications and is likely to be a major contributor to most acute CVD events in COVID-19 [22], especially in younger healthy adults. A recent review [23] highlighted a number of pathways involving localised endothelial cell dysfunction, vascular leakage and unregulated immune activation that contribute to DIC formation in ARDS in COVID-19 patients. Activation of the kallikrein-bradykinin system leading to reduced blood flow, upregulation of adhesion molecules that mediate leucocyte recruitment, activation of platelets and neutrophils, and increased inflammation and immune surveillance all potentially contribute to vascular damage (and pulmonary injury) in COVID-19 patients. SARS-CoV-2 has also been shown to target and infect endothelial cells in vascular beds in multiple tissues [24], but it remains to be confirmed whether endothelial cells in the cerebral vasculature are similarly targeted.

Most studies to date have implicated vascular dysfunction and ischaemic damage in the major neurological complications associated with COVID-19. Post-mortem neuropathological examination in 18 COVID-19 cases showed all to have acute hypoxic-ischaemic brain injury affecting the cerebrum and cerebellum, with rare foci of perivascular inflammation in two of the brains but no convincing evidence of virus within the CNS [25]. MR imaging of autopsy brains from deceased COVID-19 patients within 24 h of death revealed white matter changes including foci of haemorrhage in two cases and evidence of posterior reversible encephalopathy syndrome in another [26]. Plasma markers of neuronal and astrocyte injury (neurofilament light chain protein and glial fibrillary acidic protein) were elevated in COVID-19 patients and associated with disease severity [27]. The authors concluded that further studies were needed to assess the relationship of brain damage to ischaemic and inflammatory processes. The key unanswered question is how much damage is mediated by direct effects of virus on the CNS parenchyma or vasculature (damage that would be expected to persist after the virus is cleared from the CNS), how much is indirect CNS vascular injury mediated by immune activation, and how much is hypoxic-ischaemic damage secondary to the extracranial effects of the virus on the respiratory and cardiovascular systems.

SARS-CoV-2 infects human brain

Both SARS-CoV-2 antigen and RNA have been detected within brain tissue in human post-mortem studies, the antigen mainly within the medulla and lower cranial nerves [28]. SARS-CoV-2 was detected in cerebrospinal fluid from a patient with viral encephalitis [29] and was observed at autopsy in neural and capillary endothelial cells in COVID-19 brain tissue [30]. These observations need to be confirmed in further studies, particularly given the high Ct values used for the PCR detection of viral RNA and the difficulty of electron microscopic interpretation of virus-like particles. Although retrograde axonal transport via the olfactory bulb, associated with anosmia, is a potential route for neuroinvasion, it is likely that the cerebral vasculature plays a more important role in entry of the virus into the CNS. ACE-2, the principal SARS-CoV-2 receptor, is highly expressed by endothelial cells [31] and pericytes throughout the body [32] and analysis of publicly available databases indicates that ACE-2 is also expressed in the brain [33].

Despite apparent low levels of ACE-2 mRNA within the brain [34‐37], SARS-Cov-2 infects induced pluripotent stem cell-derived human neural stem and progenitor cells, neurospheres, and cortical neurons with brain organoids (all of which express ACE-2) [38‐41]. These data suggest that the mRNA levels do not necessary reflect ACE-2 protein or enzyme activity within the brain, although we would point out that some of the information (e.g. [38‐41]) has been published only on preprint servers; peer review may lead to modification of the conclusions. We and others have detected ACE-2 immunohistochemically within the cerebral vasculature in human post-mortem brains [38, 42] and a pre-published study by the Betsholtz lab indicates that ACE-2 is also enriched in brain pericytes [43]. In addition to ACE-2, other docking receptors for SARS-CoV-2 have been identified, including basigin (BSG, CD147) (preprint [44]) and neuropilin (NRP1) (preprint [45]), and these are highly expressed in endothelial cells and pericytes [46]. These receptors may have an important role to play, alongside or separately to ACE-2, in viral entry and disease pathogenesis (reviewed [46]).

Activation of the cerebral endothelium in a range of disease states, including AD, is associated with increased expression of integrins and selectins that are responsible for the attachment, tethering and passage of immune cells across the BBB. This leads to infiltration of brain tissue by immune cells, including neutrophils, monocytes, and lymphocytes, contributing to the pathogenesis of disease (reviewed [47]). In view of the activation of endothelium and inflammatory cell infiltration in lung and other tissues in COVID-19, it is conceivable that activation of the cerebral endothelium and infiltration by immune cells also contributes to neurological disturbance in many patients, although this too remains to be determined.

Pericytes are mural cells located within the basement membrane of microvessels [48] and communicate with endothelial cells to maintain integrity of the BBB [49] and regulate essential vascular functions: blood flow [50] and neurovascular coupling, endothelial transcytosis [51], and angiogenesis [52]. Transcriptomic analysis of murine heart [32, 53] and brain [54‐56] indicates that pericytes express high levels of ACE-2 and are therefore likely targets of SARS-CoV-2. Lung biopsies from 4 hospitalised Covid-19 patients revealed a dramatic reduction in pericyte coverage of alveolar capillaries in addition to thickening of the capillary wall [57]. Pericyte degeneration and the consequent disruption of endothelial signalling and homeostasis are likely to be important contributors to vascular instability in COVID-19 [32]. In pericyte-deficient mice (Pdgfrb^ret/ret), levels of von Willebrand factor, which promotes platelet aggregation and coagulation, are elevated, suggesting that pericyte loss contributes to the pro-angiogenic response in COVID-19 patients [43]. These studies implicate pericyte dysfunction as a mediator of pathophysiology in COVID-19. It is not yet known whether pericytes within the brain degenerate or become dysfunctional in COVID-19 patients with neurological manifestations.

A recent study has provided further evidence of the neuroinvasive potential of SARS-CoV-2 [38]. The authors demonstrated ACE-2-dependent infection of nerve cells within human brain organoids, and hypoxia-like metabolic changes and damage in neighbouring uninfected cells. Expression of humanised ACE-2 within the brain of mice experimentally infected with SARS-CoV-2 caused vascular remodelling throughout the cortex and greatly increased their mortality. The authors examined brain tissue from three COVID-19 patients and reported that SARS-CoV-2 spike protein could be detected immunohistochemically within the walls of small vessels cortical adjacent to microinfarcts. They also reported spike protein immunopositivity in some cortical neurons. However, these findings need to be confirmed.

The types of cerebral ischaemic damage seen in COVID-19 are major contributors to cognitive decline and dementia

Pre-existing dementia ranks as one of the most significant risk factors, or co-morbidities, in COVID-19. Retrospective assessment of UK health records in the UK OpenSAFELY platform indicated a hazard ratio of 2.16 (fully adjusted model) in association with pre-existing dementia/stroke [58]. An odds ratio of 3.07 was associated with dementia in a UK biobank community study [59]. The reasons for the increased risk and mortality in patients with pre-existing dementia have been well reviewed [60]. What is perhaps not as widely appreciated is that the types of brain damage seen in COVID-19 are themselves major contributors to cognitive decline and dementia.

Ischaemic brain damage is the defining pathological process in vascular dementia (VaD), and stroke is a major risk factor for dementia [61, 62]. Thromboembolic occlusion of cerebral blood vessels, a major complication of DIC, can cause a wide spectrum of neurological deficits, including cognitive impairment or dementia. Single or multiple infarcts, as a result of thromboembolism affecting major cerebral arteries, are estimated to account for approximately 20% of dementia cases associated with stroke [63]. It is probable that acute large cerebral vascular occlusion associated with hypercoagulability in severely affected COVID-19 patients will increase the risk of dementia to some extent.

Small vessel disease (SVD) accounts for about 20% of all strokes [64] but about 80% of stroke-related dementia cases [63], and is the most common cause of vascular cognitive impairment. SVD-associated neuroimaging abnormalities of the white matter and arteriolosclerosis of cerebral microvessels can be demonstrated in about 50% of all patients with dementia [65, 66]. Co-morbidities of SVD include hypertension and diabetes [67] (both also risk factors for severe COVID-19). Hypercoagulability and disseminated intravascular coagulation that affect many patients with severe COVID-19 are likely to reduce perfusion through small intracerebral vessels more than through larger ones. SARS-COV-2 induces endothelial dysfunction [23] and infects vascular beds in multiple tissues [24]. Cerebral white matter is particularly vulnerable to changes in cerebral blood flow, as would be expected in association with diffuse small vessel dysfunction and has been reported in COVID-19 [68‐70]. The integrity of subcortical white matter is critically important for maintenance of cognitive function [71, 72], and one of the consequences of white matter damage in COVID-19 is likely to be cognitive impairment. This was highlighted by the neuroradiological demonstration that damage to white matter and disruption of functional integrity in brain regions such as the hippocampus, at 3-month follow-up in recovered COVID-19 patients, was associated with memory loss [9].

The pathophysiology of SVD remains incompletely understood but damage to endothelial cells and pericytes, as well as BBB leakiness, are contributors to SVD-related brain injury (reviewed [66, 73]), which are likely to be exacerbated in severe COVID-19. Endothelial dysfunction and pericyte loss are associated with the cerebral influx and accumulation of toxic constituents of the plasma, such as fibrinogen, leading to oligodendrocyte damage and myelin loss [74]. Fibrinogen-mediated activation of the bone morphogenetic protein signalling pathway prevents maturation of oligodendrocyte precursor cells and restricts oligodendrocyte maturation and remyelination [75]. The infiltration of immune cells across a damaged BBB may also contribute to white matter damage and cognitive decline in dementia and perhaps COVID-19 (reviewed [47]). In addition, endothelial dysfunction and loss of pericytes are likely to impair the clearance of cerebral metabolites, including Aβ peptides, that are toxic when present in excess. Impaired drainage of metabolites including Aβ is implicated in the development of cerebral amyloid angiopathy and Alzheimer’s disease [76, 77] and ineffective drainage of solutes probably accounts for enlargement of perivascular spaces in patients with SVD (reviewed [78, 79] and cerebral amyloid angiopathy ([80‐82]).

Several other factors may impact on cerebral perfusion during systemic infection. Increased blood viscosity tends to slow capillary transit and limit oxygen delivery. Damage to the glycocalyx, a carbohydrate-enriched matrix on the luminal side of capillaries may impair perfusion and exacerbate ischaemia [83, 84]. Many of the deleterious alterations to small vessels in systemic infection are exacerbated by the same risk factors that predispose to severe COVID-19, such as ageing, hypertension, diabetes, and obesity.

Post-mortem and neuroimaging studies indicate that ischaemic damage to the cerebral white matter is present in up to two thirds of patients with AD [85‐87]. Although cerebral amyloid angiopathy may contribute to the damage, in most cases the ischaemia-related damage probably results from a combination of arteriolosclerotic SVD and non-structural vascular dysfunction (reviewed [88]). A series of recent neuroimaging studies has shown that ischaemic white matter damage occurs at a very early stage of AD, accelerates progression of the disease and contributes to the cognitive decline [89‐93]. These clinical observations are supported by experimental studies showing that brain ischaemia accelerates Aβ accumulation, through a combination of dysregulated processing of amyloid-β precursor protein (APP) and impaired Aβ clearance (reviewed [87]) and that, in turn, Aβ peptides mediate vasoconstriction, by inducing contraction of pericytes [94] and vascular smooth muscle cells [95]. Studies of microvascular endothelial cell monolayers [96, 97], human APP transgenic mouse models [98], and on human post-mortem brain tissue [99] indicate that Aβ peptides also impair BBB function, in part by reducing expression of tight junction proteins. Pericyte degeneration in AD is associated with BBB breakdown [100‐102]. Pericyte loss accelerates Aβ pathology and induces tau pathology and cognitive decline in human APP mice [103]. In human brain tissue from AD patients, a decline in the level of the pericyte marker, platelet-derived growth factor-β (PDGFRβ), was associated with increased Aβ level and reduced cerebral perfusion [104]. Aβ peptides are toxic to human brain pericytes in culture [105] and analysis of cerebrospinal fluid indicates that the level of soluble PDGFRβ, a marker of pericyte injury and BBB leakiness, is elevated in the elderly in association with the earliest detectable changes in cognitive performance [89, 90].

There is increasing evidence that cerebral hypoperfusion is also linked to tau pathology. In clinically normal adults with positron emission tomography (PET) evidence of cerebral Aβ accumulation, those who also had an increased cardiovascular disease risk score were significantly more likely to show evidence of tau accumulation as well [106]. In patients with mild cognitive impairment, increased cerebrovascular burden was associated with elevated PET-Tau signal and worse cognitive performance, independently of Aβ-PET [107]. Several experimental studies have shown that modelling of cerebral hypoperfusion increases tau phosphorylation: in adult Wistar rats [108], transgenic mice with Aβ and tau accumulation [109], and rat and human brain slices exposed to oxygen and glucose deprivation [110]. In a recent autopsy study, elevated levels of soluble tau and insoluble phospho-tau were associated with lower levels of endothelial tight junction proteins, claudin-5 and occludin, in AD [111]. Tau-overexpressing mice were shown to have abnormal blood vessel morphology and increased vessel density [112]. A recent study found impaired neurovascular coupling, prior to neurodegeneration, in young (2–3 months) mice expressing mutant tau [113]. There are therefore clinical and experimental data suggesting a bidirectional relationship between cerebral vascular dysfunction and pathological tau. There is evidence from recent studies that TDP-43 pathology, likewise, is associated with cerebral vascular dysfunction, including pericyte loss and small vessel disease [114, 115]. Lastly, cerebral ischaemia induces phosphorylation of α-synuclein at serine-129; this is the predominant disease-related modification of α-synuclein in Lewy bodies and neurites in Parkinson disease, and dementia with Lewy bodies, and also is significantly associated with concomitant AD pathology in these Lewy body diseases [116].

Both cerebral ischaemia and systemic inflammation can induce endothelial activation, with increased expression of integrins and selectins leading to adhesion and transendothelial migration of leukocytes into the brain parenchyma. Endothelial activation, with recruitment of leukocytes, has also been shown in AD [47, 117]. Leukocytes enter the brain through post-capillary venules within the parenchyma, and to a lesser extent, vessels in the leptomeninges and choroid plexus. Activated neutrophils in cerebral vessels and parenchyma were found to contribute to gliosis and cognitive impairment in human APP mice [118]. In APP/PS1 mice, respiratory infection increased infiltration of the brain by interferon γ- and interleukin-17-producing T cells and natural killer T cells, accompanied by gliosis and enhanced deposition of Aβ [119]. Monocytes are the most common type of peripheral immune cell that migrates via the BBB into the brain in AD. CCL2, the major ligand for CCR2 expressed on monocytes, is upregulated in microvessels in AD and plays a role in Aβ clearance (reviewed [47]). Whether endothelial activation predicts not only acute but also longer neurological complications (including dementia) in COVID-19 remains to be determined.

Angiotensin-converting enzyme-2-mediated entry of SARS-CoV-2 into human cells and activation of the classical renin-angiotensin system

SARS-CoV-2 cell attachment and entry are initiated by binding of the virus to angiotensin-converting enzyme-2 (ACE-2) [120]. The expression of ACE-2 at the cell surface is therefore likely to be a critical determinant of viral tropism and pathobiology in COVID-19. ACE-2 is expressed in stem cell-derived neurons [121] and in neuronal and glial cells within the brain [33, 42], potentially enabling virus entry and spread through the cribriform plate by retrograde axonal transport along olfactory nerves [33], or from sensory fibres that pass from the lungs to the brain stem via the vagal nerve and nodose ganglion [4]. ACE-2 is also expressed in the temporal lobe and hippocampus—brain regions that are involved in cognition and memory and are affected in AD [122]. Neuronal uptake and spread within the brain were demonstrated in human ACE-2 transgenic mice infected with SARS-CoV-1 [123] and SARS-CoV-2 [124]. However, as noted above, ACE-2 is also highly expressed on endothelial cells and pericytes, and haematogenous spread followed by endothelial uptake or influx of infected peripheral immune cells are further possible routes of entry of virus into the brain.

During SARS-Cov-1 infection, ACE-2 is cleaved from the cell surface [125] by ADAM-17 [126] during viral entry [127]. Although likely, it remains to be determined whether SARS-CoV-2 similarly results in loss of cell membrane-associated ACE-2. Ordinarily, ACE-2 is a key effector of the regulatory RAS that counters the actions of the classical RAS and reduces the risk of cardiovascular disease (reviewed [128, 129]), stroke [130‐132], and dementia [133] (Fig. 2). ACE-2 is reduced in Alzheimer’s disease (AD) [42] and cognitive decline is pronounced in ACE-2 knock-out mice [134]. If SARS-CoV-2 entry leads to loss of ACE-2 (as in SARS), angiotensin II-mediated classical RAS activation would increase the risk of cerebrovascular and neurological disturbances in COVID-19 patients. This mechanism has also been proposed to explain other vascular and pulmonary manifestations of COVID-19 [135, 136]. Internalisation of ACE2, as a result of angiotensin II activation of angiotensin receptor type 1 (AT1R), may further exacerbate damage [137]. The available reservoir of ACE-2 may be an important determinant of clinical outcome in COVID-19. Studies in rodents indicate that ACE-2 expression declines with age and is lower in males [138‐141]. In contrast, oestrogen upregulates ACE-2, which could help to protect pre-menopausal women against severe complications of COVID-19 [142, 143]. It may be relevant that most co-morbidities that increase the risk of complications in COVID-19, including hypertension, obesity, and diabetes, are associated overactivity of the classical RAS. Indeed ethnicity and genetic variations also influence baseline ACE-2 levels [144] and could provide a biological explanation as to why some ethnic groups are at higher risk of COVID-19 [145]. The hypothesis would explain why angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme-1 inhibitors (ACE-Is), which downregulate the classical RAS by either blocking angiotensin II (Ang-II) signalling or Ang-II synthesis, respectively, and upregulate ACE-2, may reduce mortality in COVID-19 patients [146, 147].

An imbalance in RAS contributes to acute ARDS (reviewed [148]), which develops in a high proportion of the COVID-19 patients who develop viral pneumonia [149, 150]. ARDS patients show overactivity of the classical RAS [151] and reduction of ACE-2 [152, 153]. Increased Ang-II-mediated AT1R signalling, which drives inflammation [154], is likely to contribute to the inflammatory storm in severe COVID-19. Lung tissue damage in ARDS can be reduced by ARBs and ACEIs [155] and by administration of recombinant ACE-2 [152, 156]. ACE-2 catalyses the formation of Ang-(1-7), which binds to Mas receptor; both ACE-2 activation [157] and Ang-(1-7) activation of Mas receptor attenuate lung injury in ARDS [158]. Ang-(1-7) activates ERK1/2 signalling and modulates interleukin (IL)-10 expression, protecting against lung damage (reviewed [159]).

Recombinant soluble ACE-2 (rsACE-2) shows therapeutic promise in severe COVID-19 infection; administration was reported to reduce viral titre and serum Ang-II, elevate serum Ang-(1-7) levels and markedly reduce pro-inflammatory cytokines [160]. In addition to preventing viral binding, rsACE-2-mediated reduction in Ang-II is likely to prevent AT1R-mediated ADAM-17 cleavage of membrane-bound ACE-2 and restore balance in the RAS [161].

Potential neurological consequences of increased classical renin-angiotensin system activation in COVID-19

The RAS is expressed and functions independently within the brain. Overactivation of the classical RAS, with elevated ACE-1 and Ang-II, has been demonstrated in post-mortem human brain tissue in AD [162‐164]. Cerebroventricular infusion of Ang-II into adult Wistar rats promoted Aβ production and tau pathology [165, 166], and ARBs and ACEIs protect against cognitive decline and disease pathology in transgenic APP mouse models of AD (reviewed [167]). We previously reported that reduction of ACE-2 in brain tissue in AD correlated strongly with parenchymal Aβ and tau levels and with increased ACE-1 activity [42]. We and others have since shown that induction of ACE-2, or administration of Ang-(1-7) or peptide analogues, protects against Aβ-related cognitive decline in mice associated with reduced neuroinflammation and oxidative stress [133, 168, 169].

The RAS is a critical regulator of vascular function. Ang-II binds to AT1R on vascular smooth muscle cells [170, 171] to induce cerebral artery constriction [172], and on pericytes to cause constriction of microvessels [173, 174]. Ang-II also modulates BBB permeability: AT1R signalling induces leakiness in endothelial cell culture models of the BBB [175] and Ang-II infusion causes BBB leakiness in mice that can be reversed by adding a superoxide scavenger, indicating a role for oxidative stress [176]. Several mediators of BBB leakiness, including vascular endothelial growth factor and matrix metalloproteinase (MMP)-2 and MMP-9, are induced by Ang-II [177‐179]. In mice, Ang-II was shown to impair neurovascular coupling (i.e. the blood flow response to increased neural activity) in the somatosensory cortex [180] and to interfere with cerebral autoregulation [181, 182]. The accumulation of ACE-1 in the extracellular matrix around cerebral arterioles (particularly in AD patients with cerebral amyloid angiopathy) suggests that locally produced (as well as circulatory) Ang-II participates in cerebrovascular dysfunction mediated by overactivation of the classical RAS [163].

Overactivation of the classical RAS may also reduce clearance of Aβ. Intra-mural peri-arterial drainage (IPAD) and para-vascular glymphatic channels have been implicated in the removal of Aβ from the brain [183‐185]. The functioning of these drainage pathways depends on the polarised expression of aquaporin-4 in astrocytic endfeet [186], which is regulated by pericytes [187]. Focal absence of pericytes results in the redistribution of aquaporin-4 to the cell soma [51]. The RAS modulates aquaporin-4 expression in astrocytes [188], and Ang-II was shown to act via AT1R to reduce ACE-2 expression in astrocyte cultures [189]. These alterations in pericyte and astrocyte function are likely to impair the clearance of Aβ. It remains to be determined whether this occurs in COVID-19.

Neuroinflammation is strongly implicated in the development of AD. Genome-wide association studies have identified several inflammatory pathway genes as risk factors for AD [190, 191]. Complement [192] and inflammasome activation [193, 194] are likely to contribute to cerebrovascular dysfunction, neuronal toxicity, and the accumulation of Aβ and tau in AD. Ang-II activates the complement system [195, 196] and the NLRP3 inflammasome [197], and both complement [198] and inflammasome activation [11] have been proposed to contribute to neurological disease in COVID-19 patients. A recent in silico study implicated SARS-CoV-2 activation of Toll-like receptor 4 (TLR4) as a major contributor to the inflammatory response in COVID-19 [199]. Ang-II upregulates TLR4 [200], which is a critical determinant of Ang-II-mediated vascular remodelling [201]. Blocking of TLR4 signalling delayed the development of Ang-II-mediated hypertension in rats and was associated with a dramatic increase in ACE-2 [202]. Pericytes express high levels of TL4R, activated by free long-chain fatty-acids [203]. The spike protein of SARS-CoV-2 has been shown to bind to linoleic acid, affecting the conformation of the protein and possibly the binding of the virus to ACE-2 (pre-published study [204]). It may therefore be relevant that linoleic acid is reduced in both COVID-19 [205] and AD [206], potentially influencing the progression of both diseases. Ang-II also acts as a molecular switch regulating microglial phenotype—switching between an M1 (pro-inflammatory) and M2 (immunoregulatory) protective phagocytic phenotype [207] which is relevant to AD pathogenesis [208]. The role of microglia in neurological manifestations of COVID-19 has yet to be fully explored.

Ang-II-mediated endothelial activation promotes the binding and diapedesis of leukocytes across the BBB; these effects are mitigated by Ang-1-7 [209]. Pericytes too have immune-regulating properties (reviewed in [210]) and their localisation within the cerebral vasculature suggests that they may serve a ‘gate-keeper’ role in regulating immune cell infiltration. Although pericytes express ACE-2, it remains to be established whether they are targeted by SARS-CoV-2. Because of the pivotal role of pericytes in regulation of cerebrovascular function (and perhaps immune cell infiltration), it is likely that virus-induced pericyte damage would compromise cerebral perfusion, BBB integrity, and immune regulation. In addition to vascular effects, angiotensin peptides derived from Ang-II, including Ang-IV and Ang-(1-7), have neuromodulatory [211] (reviewed [212]) and neuroprotective properties (reviewed [213]). Ang-(1-7) activation of Mas (regulatory RAS) receptor and Ang-IV activation of the c-Met and insulin-regulated aminopeptidase receptors (reviewed [214]) limit tissue damage in models of stroke (reviewed [215, 216]). Similarly, ACE-2 activation and/or Ang-(1-7) infusion prevents cognitive decline and disease pathology in animal models of Aβ accumulation [133, 169, 217, 218], independent of changes in blood pressure. There is therefore a wide range of mechanisms through which reduced regulatory RAS signalling may exacerbate brain damage in COVID-19.

Is APOE ε4, an established risk factor for AD and vascular dysfunction, also a risk factor for COVID-19?

APOE polymorphism greatly influences the risk of developing AD: the risk is increased with APOE ε4 and decreased with APOE ε2 [219, 220]. The physiological roles of the encoded apolipoprotein (apolipoprotein E, ApoE) have still not been fully defined. Recent studies indicate that possession of APOE ε4 is associated with cerebrovascular dysfunction, including BBB leakiness and pericyte degeneration [221] and cerebral amyloid angiopathy with capillary involvement [222]. A recent UK study reported that there was a higher prevalence of COVID-19 in people who were carriers of APOE ε4 [223]. We previously showed that APOE ε4 individuals also have lowest ACE-2 activity [42]. Pericyte expression of APOE ε4 was reported to promote BBB leakiness because of deficient basement membrane formation [224]. Moreover, possession of APOE ε4 is associated with reduced cerebral blood flow and increased subcortical ischaemic white matter damage [225, 226], as well as neuroinflammation in AD (reviewed [227]). Future studies should aim to clarify the relationships between APOE ε4, COVID-19, and cerebral vascular dysfunction and AD.

Potential upregulation of ADAM-17 in COVID-19

ACE-2 is cleaved by ADAM-17 upon SARS-Cov-1 entry into cells [125‐127]. It seems likely that this also occurs upon SARS-Cov-2 cell entry, although the data are not yet available. Ang-II-mediated activation of ADAM-17 and shedding of ACE-2 points to a positive feedback loop in which increased Ang-II level is associated with loss of ACE-2 [228]. Yet, it is worthy of note that ADAM-17 cleaves many cell-associated proteins that are required for proper function of the vasculature including the ApoE receptor, low-density lipoprotein receptor-related protein 1 (LRP-1), involved in transendothelial clearance of Aβ (facilitated by ApoE), and PDGFRβ, needed for maintenance of pericytes. Upregulation of ADAM-17 may therefore potentially exacerbate vascular dysfunction in COVID-19. ADAM-17 also acts as one of the α-secretases and cleaves APP, preventing the generation of Aβ (reviewed [229]). The complex divergent roles of ADAM-17 in AD and potentially COVID-19 require further investigation.

Clinical management, clinical trials and possible future targets for therapeutic intervention in COVID-19 patients

In severe COVID-19, patients present with pneumonia and those most severely affected develop ARDS with features of septic shock and multiple organ failure, requiring oxygen treatment and/or mechanical ventilation. Infection-induced inflammatory and vascular changes associated with coagulopathy and thrombosis, including venous thromboembolism (VTE), DIC and thrombotic microangiopathy with thromboembolic microvascular complications, are common complications of severe COVID-19, as illustrated by reports of VTE in 25–27% hospitalised patients [230, 231]. The International Society on Thrombosis and Hemostasis (ISTH) recommends measuring levels of d-dimer, prothrombin time, partial thromboplastin time and platelet count, in hospitalised COVID-19 patients [232]. A retrospective study in Wuhan, China, at the beginning of the pandemic, found that mortality rates were lower in patients given low-molecular weight heparin [233]. Clinical management of severe COVID-19 patients now routinely includes low-dose sub-cutaneous heparin [233] and/or thrombotic prophylaxis [234], unless patients are at increased risk of bleeding.

Lymphopenia with marked loss of regulatory T and B cells and natural killer cells, reduction in monocytes, eosinophils and basophils, and an increase in neutrophils are typical in severe COVID-19 (reviewed [235]). There are also elevated levels of pro-inflammatory cytokines, sometimes marked (a so-called cytokine storm). Convalescent plasma [236] and plasma exchange [237, 238] improve survival rates in severe disease, and immunomodulatory therapies such as tocilizumab, a monoclonal antibody against the IL-6 receptor [239], and sarilumab, an IL-6 receptor antagonist [240], may offer protection and are currently undergoing clinical trials. Neutralising antibodies targeting other pro-inflammatory cytokines (IL-1, IL-17) may also offer protection, as too may potential inhibitors of complement system activation. Intravenous transplantation of mesenchymal stems cells was shown to improve the outcome of COV-19 patients with pneumonia in 7 COVID-19 patients in Beijing, China [241]. It seems possible that mesenchymal stem cells might also ameliorate brain injury in severe COVID-19, given their immunomodulatory and anti-inflammatory properties, and ability to attenuate BBB damage and neuroinflammation after cerebral ischaemia [242‐244].

There is continued debate on the role of systemic or inhaled corticosteroids in COVID-19 patients. Although earlier studies indicated a lack of benefit from corticosteroids [245], a randomised clinical trial reported by the RECOVERY collaborative group, Oxford, UK, found that systemic dexamethasone reduced mortality in severely affected COVID-19 patients [246]. Inhaled steroids had previously been shown to reduce inflammation and tissue injury in ARDS [247] (reviewed [248]). In addition to their inherent anti-inflammatory properties, steroids may have anti-viral properties [249]. Ciclesonide, an inhaled corticosteroid, was shown to suppress replication of MERS-CoV, SARS-CoV and SARS-CoV-2 in vitro [250].

The expression and activity of interferon-β (IFN-β), an endogenous protein with anti-viral and anti-inflammatory properties, is impaired in COVID-19 [251]. Interferon inhibits SARS-CoV-2 replication in vitro [252]. In a Phase II clinical trial, IFN-β in combination with anti-viral drugs shortened the duration of viral shedding and length of hospital admission [253]. A pharmaceutical company based in the UK, Synairgen, reported a lower risk of requiring ventilation, and reduction in mortality by about 79%, in a Phase II clinical trial of SNG001, an inhaled form of IFN-β (these data are currently unpublished).

Since ACE-2 is a receptor for SARS-CoV-2, and ACEIs and ARBs are predicted to increase ACE-2 expression, it was initially feared that the use of these drugs might exacerbate COVID-19 [254]. Recent meta-analyses have instead suggested that RAS-targeting medications are protective in COVID-19 [146, 147, 255]. This is likely to be a due to the protective role of ACE-2 in lowering or preventing overactivation of the classical RAS and minimising consequent Ang-II-mediated ischaemic and inflammatory damage, as outlined above. Several clinical trials have been registered with the National Institutes of Health (NIH) to test ARBs such as losartan in COVID-19 patients: NCT04335123, NCT04312009 and NCT04311177. Two studies are also investigating the impact of discontinuation of ACE-Is on COVID-19 (EudraCT numbers 2020-001544-26 and 2020-001206-35). Boosting the regulatory arm of the RAS may ameliorate COVID-19 because of the protective effects of ACE-2 and Ang-(1-7); interventional trials with recombinant human ACE2 (rhACE2) and Ang-(1–7) have also been registered (NCT04287686 and NCT04332666, respectively), although the rhACE2 study seeking to recruit people between the ages 18–80 years in China has since been withdrawn. A further rhACE2 study (2020-001172-15) is registered on the EU Clinical trials register. Other strategies being explored include several studies seeking to inhibit TMPRSS2. Studies that could include TL4R blockers and ADAM-17 inhibitors might also be worthy of future study. For a comprehensive review of the pharmacological targets that are currently being investigated as potential interventions and treatments in COVID-19, the reader should refer to recent reviews [256‐258].

Conclusion

Cerebral vascular disease is emerging as a major complication of severe COVID-19. This is likely to cause lasting brain damage and to increase the risk of stroke and vascular cognitive impairment. Several of the metabolic abnormalities that affect COVID-19 patients may also increase the risk of developing AD. Dementia and COVID-19 share many co-morbidities and risk factors, including age, gender, hypertension, diabetes, obesity and possession of APOE ε4—most of which are associated with an overactive RAS, cerebrovascular dysfunction and neuroinflammation. These shared co-morbidities and similar mechanisms may also explain the high incidence and increased rates of mortality amongst people with dementia [59, 259, 260]. There is urgent need for research to better understand the pathogenesis of neurological disturbances in COVID-19, some of which have probably been covert and the prevalence of which may be considerably underestimated. This understanding is essential to establish the long-term consequences from the disease (including the potential for increased risk of dementia in some cases) and to identify means of preventing or ameliorating the brain damage.

Acknowledgements

We thank the Medical Research Council, BRACE (Bristol Research into Alzheimer’s and Care of the Elderly) and ABBUK (Alzheimer’s Brain Bank UK, which funds Brains for Dementia Research) for supporting the work of the South West Dementia Brain Bank.

Not applicable.

Competing interests

The authors declare no competing interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, Talbot PJ. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1):14. https://doi.org/10.3390/v12010014.

Glass WG, et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol. 2004;173(6):4030–9.PubMedCrossRef

Gu J, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–24.PubMedPubMedCentralCrossRef

Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–5.PubMedCrossRef

Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767–83. https://doi.org/10.1016/S1474-4422(20)30221-0.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–90. https://doi.org/10.1001/jamaneurol.2020.1127.

Helms J, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268–70.PubMedCrossRef

Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, Easton A, Breen G, Zandi M, Coles JP, Manji H, Al-Shahi Salman R, Menon DK, Nicholson TR, Benjamin LA, Carson A, Smith C, Turner MR, Solomon T, Kneen R, Pett SL, Galea I, Thomas RH, Michael BD. CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875–82. https://doi.org/10.1016/S2215-0366(20)30287-X.

Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, Jia T, Zhao Y, Wang D, Xiao A, Yin B. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMed, 2020;25:100484. https://doi.org/10.1016/j.eclinm.2020.100484.

10.

Pereira A. Long-term neurological threats of COVID-19: a call to update the thinking about the outcomes of the coronavirus pandemic. Front Neurol. 2020;11:308.PubMedPubMedCentralCrossRef

11.

Heneka MT, et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69.PubMedPubMedCentralCrossRef

12.

Lindlau A, et al. Predictors of hippocampal atrophy in critically ill patients. Eur J Neurol. 2015;22(2):410–5.PubMedCrossRef

13.

Iwashyna TJ, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787–94.PubMedPubMedCentralCrossRef

14.

Widmann CN, Heneka MT. Long-term cerebral consequences of sepsis. Lancet Neurol. 2014;13(6):630–6.PubMedCrossRef

15.

Girard TD, et al. Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. Lancet Respir Med. 2018;6(3):213–22.PubMedPubMedCentralCrossRef

16.

Sasannejad C, Ely EW, Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Crit Care. 2019;23(1):352.PubMedPubMedCentralCrossRef

17.

Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, Jayaseelan DL, Kumar G, Raftopoulos RE, Zambreanu L, Vivekanandam V, Khoo A, Geraldes R, Chinthapalli K, Boyd E, Tuzlali H, Price G, Christofi G, Morrow J, McNamara P, McLoughlin B, Lim ST, Mehta PR, Levee V, Keddie S, Yong W, Trip SA, Foulkes AJM, Hotton G, Miller TD, Everitt AD, Carswell C, Davies NWS, Yoong M, Attwell D, Sreedharan J, Silber E, Schott JM, Chandratheva A, Perry RJ, Simister R, Checkley A, Longley N, Farmer SF, Carletti F, Houlihan C, Thom M, Lunn MP, Spillane J, Howard R, Vincent A, Werring DJ, Hoskote C, Jäger HR, Manji H, Zandi MS. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143(10):3104–20. https://doi.org/10.1093/brain/awaa240.

18.

Hernández-Fernández F, Sandoval Valencia H, Barbella-Aponte RA, Collado-Jiménez R, Ayo-Martín Ó, Barrena C, Molina-Nuevo JD, García-García J, Lozano-Setién E, Alcahut-Rodriguez C, Martínez-Martín Á, Sánchez-López A, Segura T. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain. 2020;143(10):3089–103. https://doi.org/10.1093/brain/awaa239.

19.

Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, Alberici A, Baldelli E, Benini M, Bonacina S, Brambilla L, Caratozzolo S, Cortinovis M, Costa A, Cotti Piccinelli S, Cottini E, Cristillo V, Delrio I, Filosto M, Gamba M, Gazzina S, Gilberti N, Gipponi S, Imarisio A, Invernizzi P, Leggio U, Leonardi M, Liberini P, Locatelli M, Masciocchi S, Poli L, Rao R, Risi B, Rozzini L, Scalvini A, Schiano di Cola F, Spezi R, Vergani V, Volonghi I, Zoppi N, Borroni B, Magoni M, Pezzini A, Padovani A. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020;95(7):e910–20. https://doi.org/10.1212/WNL.0000000000009848.

20.

Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke. 2020;15(4):385–9.PubMedCrossRef

21.

Oxley TJ, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60.PubMedCrossRef

22.

Reddy ST, et al. Cerebrovascular disease in patients with COVID-19: a review of the literature and case series. Case Rep Neurol. 2020;12(2):199–209.PubMedPubMedCentralCrossRef

23.

Teuwen LA, et al. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389–91.PubMedCrossRefPubMedCentral

24.

Varga Z, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.PubMedPubMedCentralCrossRef

25.

Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RF Jr, Sabeti P. Neuropathological Features of Covid-19. N Engl J Med. 2020;383(10):98–92. https://doi.org/10.1056/NEJMc2019373.

26.

Coolen T, Lolli V, Sadeghi N, Rovai A, Trotta N, Taccone FS, Creteur J, Henrard S, Goffard JC, Dewitte O, Naeije G, Goldman S, De Tiège X. Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology. 2020;95(14):e2016–27. https://doi.org/10.1212/WNL.0000000000010116.

27.

Kanberg N, Ashton NJ, Andersson LM, Yilmaz A, Lindh M, Nilsson S, Price RW, Blennow K, Zetterberg H, Gisslén M. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95(12):e1754–9. https://doi.org/10.1212/WNL.0000000000010111.

28.

Matschke J, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919–29.PubMedPubMedCentralCrossRef

29.

Moriguchi T, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55–8.PubMedPubMedCentralCrossRef

30.

Paniz-Mondolfi A, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92(7):699–702.PubMedCrossRef

31.

Hamming I, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.PubMedPubMedCentralCrossRef

32.

Chen L, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–100.CrossRefPubMed

33.

Baig AM, et al. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995–8.PubMedCrossRef

34.

Li MY, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45.PubMedPubMedCentralCrossRef

35.

Qi F, et al. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526(1):135–40.PubMedPubMedCentralCrossRef

36.

Sungnak W, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7.CrossRefPubMedPubMedCentral

37.

Chen R, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. BioRxiv. 2020; https://doi.org/10.1101/2020.04.07.030650.

38.

Song E, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. BioRxiv. 2020; https://doi.org/10.1101/2020.06.25.169946.

39.

Zhang BZ, Chu H, Han S, Shuai H, Deng J, Hu YF, Gong HR, Lee AC, Zou Z, Yau T, Wu W, Hung IF, Chan JF, Yuen KY, Huang JD. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020;30(10):928–31. https://doi.org/10.1038/s41422-020-0390-x.

40.

Kase Y, Okano H. Expression of ACE2 and a viral virulence-regulating factor CCN family member 1 in human iPSC-derived neural cells: implications for COVID-19-related CNS disorders. Inflamm Regen. 2020;40:32. https://doi.org/10.1186/s41232-020-00143-6.

41.

Ramani, A., et al., SARS-CoV-2 targets cortical neurons of 3D human brain organoids and shows neurodegeneration-like effects BioRxiv, 2020. doi: https://doi.org/10.1101/2020.05.20.106575doi.

42.

Kehoe PG, et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-beta and tau pathology. Alzheimers Res Ther. 2016;8(1):50.PubMedPubMedCentralCrossRef

43.

He, L., et al., Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 – implications for microvascular inflammation and hypercoagulopathy in COVID-19 patients. prepublished bioRxiv doi: https://doi.org/10.1101/2020.05.11.0885002020.

44.

Wang, K., et al., SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. doi: https://doi.org/10.1101/2020.03.14.9883452020.

45.

Cantuti-Castelvetri L, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. BioRxix. 2020; https://doi.org/10.1101/2020.06.07.137802.

46.

Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the Nervous System. Cell. 2020;183(1):16-27.e1. https://doi.org/10.1016/j.cell.2020.08.028.

47.

Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer’s disease. Neurobiol Dis. 2017;107:41–56.PubMedPubMedCentralCrossRef

48.

Attwell D, et al. What is a pericyte? J Cereb Blood Flow Metab. 2016;36(2):451–5.PubMedCrossRef

49.

Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19(6):771–83.PubMedPubMedCentralCrossRef

50.

Hall CN, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508(7494):55–60.PubMedPubMedCentralCrossRef

51.

Armulik A, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557–61.PubMedCrossRef

52.

Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol. 2011;55(3):261–8.PubMedCrossRef

53.

Ziegler CGK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–35. e19.PubMedPubMedCentralCrossRef

54.

He L, et al. Single-cell RNA sequencing of mouse brain and lung vascular and vessel-associated cell types. Sci Data. 2018;5:180160.PubMedPubMedCentralCrossRef

55.

He L, et al. Analysis of the brain mural cell transcriptome. Sci Rep. 2016;6:35108.PubMedPubMedCentralCrossRef

56.

Vanlandewijck M, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554(7693):475–80.CrossRefPubMed

57.

Cardot-Leccia N, Hubiche T, Dellamonica J, Burel-Vandenbos F, Passeron T. Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection. Intensive Care Med. 2020;46(9):1777–8. https://doi.org/10.1007/s00134-020-06147-7.

58.

Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.PubMedCrossRefPubMedCentral

59.

Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo CL, Kuchel GA, Melzer D. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2224–30. https://doi.org/10.1093/gerona/glaa183.

60.

Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, Biessels GJ, Chen C, Cordonnier C, Dichgans M, Dominguez J, Gorelick PB, Kim S, Kwok T, Greenberg SM, Jia J, Kalaria R, Kivipelto M, Naegandran K, Lam LCW, Lam BYK, Lee ATC, Markus HS, O'Brien J, Pai MC, Pantoni L, Sachdev P, Skoog I, Smith EE, Srikanth V, Suh GH, Wardlaw J, Ko H, Black SE, Scheltens P. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020;16(11):1571–81. https://doi.org/10.1002/alz.12143.

61.

Pendlebury ST, Rothwell PM, Oxford Vascular S. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular study. Lancet Neurol. 2019;18(3):248–58.PubMedPubMedCentralCrossRef

62.

Mijajlovic MD, et al. Post-stroke dementia - a comprehensive review. BMC Med. 2017;15(1):11.PubMedPubMedCentralCrossRef

63.

Staekenborg SS, et al. Small vessel versus large vessel vascular dementia: risk factors and MRI findings. J Neurol. 2008;255(11):1644–51. discussion 1813-4.PubMedCrossRef

64.

Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke. 1997;28(3):491–9.PubMedCrossRef

65.

Gorelick PB, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.PubMedPubMedCentralCrossRef

66.

Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684–96.PubMedCrossRef

67.

Ostergaard L, et al. Cerebral small vessel disease: capillary pathways to stroke and cognitive decline. J Cereb Blood Flow Metab. 2016;36(2):302–25.PubMedCrossRef

68.

Brun G, Hak JF, Coze S, Kaphan E, Carvelli J, Girard N, Stellmann JP. COVID-19-White matter and globus pallidum lesions: demyelination or small-vessel vasculitis? Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e777. https://doi.org/10.1212/NXI.0000000000000777.

69.

Reichard RR, et al. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020;140(1):1–6.PubMedCrossRefPubMedCentral

70.

Lang M, Buch K, Li MD, Mehan WA Jr, Lang AL, Leslie-Mazwi TM, Rincon SP. Leukoencephalopathy Associated with Severe COVID-19 Infection: Sequela of Hypoxemia? AJNR Am J Neuroradiol. 2020;41(9):1641–5. https://doi.org/10.3174/ajnr.A6671.

71.

Bennett IJ, Madden DJ. Disconnected aging: cerebral white matter integrity and age-related differences in cognition. Neuroscience. 2014;276:187–205.PubMedCrossRef

72.

Ystad M, et al. Cortico-striatal connectivity and cognition in normal aging: a combined DTI and resting state fMRI study. Neuroimage. 2011;55(1):24–31.PubMedCrossRef

73.

Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12(5):483–97.PubMedCrossRef

74.

Montagne A, et al. Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med. 2018;24(3):326–37.PubMedPubMedCentralCrossRef

75.

Petersen MA, et al. Fibrinogen activates BMP signaling in oligodendrocyte progenitor cells and inhibits remyelination after vascular damage. Neuron. 2017;96(5):1003–12. e7.PubMedPubMedCentralCrossRef

76.

Keable A, et al. Deposition of amyloid β in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. Biochim Biophys Acta. 2016;1862(5):1037–46.PubMedPubMedCentralCrossRef

77.

Weller RO, et al. Perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol. 2008;18(2):253–66.PubMedCrossRef

78.

Brown R, et al. Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovasc Res. 2018;114(11):1462–73.PubMedPubMedCentralCrossRef

79.

Mestre H, et al. Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin Sci (Lond). 2017;131(17):2257–74.CrossRef

80.

Charidimou A, et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology. 2017;88(12):1157–64.PubMedPubMedCentralCrossRef

81.

Charidimou A, et al. White matter perivascular spaces are related to cortical superficial siderosis in cerebral amyloid angiopathy. Stroke. 2014;45(10):2930–5.PubMedCrossRef

82.

Charidimou A, et al. White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology. 2014;82(1):57–62.PubMedPubMedCentralCrossRef

83.

Czarnowska E, Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Involvement of oxygen free radicals. Basic Res Cardiol. 1995;90(5):357–64.PubMedCrossRef

84.

Ishiharajima S, et al. Early membrane damage during ischemia in rat heart. Exp Mol Pathol. 1986;44(1):1–6.PubMedCrossRef

85.

Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease--lessons from pathology. BMC Med. 2014;12:206.PubMedPubMedCentralCrossRef

86.

Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol. 1986;19(3):253–62.PubMedCrossRef

87.

Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer’s disease. Acta Neuropathol. 2016;131(5):645–58.PubMedCrossRef

88.

Love S, Miners JS. Small vessel disease, neurovascular regulation and cognitive impairment: post-mortem studies reveal a complex relationship, still poorly understood. Clin Sci (Lond). 2017;131(14):1579–89.CrossRef

89.

Montagne A, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296–302.PubMedPubMedCentralCrossRef

90.

Nation DA, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270–6.PubMedPubMedCentralCrossRef

91.

Lee S, et al. White matter hyperintensities are a core feature of Alzheimer’s disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol. 2016;79(6):929–39.PubMedPubMedCentralCrossRef

92.

Lee S, et al. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer’s disease. Plos One. 2018;13(5):e0195838.PubMedPubMedCentralCrossRef

93.

Benzinger TL, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502–9.PubMedPubMedCentralCrossRef

94.

Nortley R, Korte N, Izquierdo P, Hirunpattarasilp C, Mishra A, Jaunmuktane Z, Kyrargyri V, Pfeiffer T, Khennouf L, Madry C, Gong H, Richard-Loendt A, Huang W, Saito T, Saido TC, Brandner S, Sethi H, Attwell D. Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes. Science. 2019;365(6450):eaav9518. https://doi.org/10.1126/science.aav9518.

95.

Hald ES, Timm CD, Alford PW. Amyloid Beta Influences Vascular Smooth Muscle Contractility and Mechanoadaptation. J Biomech Eng. 2016;138(11). https://doi.org/10.1115/1.4034560.

96.

Marco S, Skaper SD. Amyloid β-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett. 2006;401(3):219–24.PubMedCrossRef

97.

Tai LM, et al. Amyloid-β-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med. 2010;14(5):1101–12.PubMed

98.

Biron KE, et al. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer’s disease. Plos One. 2011;6(8):e23789.PubMedPubMedCentralCrossRef

99.

Hartz AM, et al. Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke. 2012;43(2):514–23.PubMedCrossRef

100.

Halliday MR, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. J Cereb Blood Flow Metab. 2016;36(1):216–27.PubMedPubMedCentralCrossRef

101.

Sengillo JD, et al. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer’s disease. Brain Pathol. 2013;23(3):303–10.PubMedCrossRef

102.

Ding R, Hase Y, Ameen-Ali KE, Ndung'u M, Stevenson W, Barsby J, Gourlay R, Akinyemi T, Akinyemi R, Uemura MT, Polvikoski T, Mukaetova-Ladinska E, Ihara M, Kalaria RN. Loss of capillary pericytes and the blood-brain barrier in white matter in poststroke and vascular dementias and Alzheimer's disease. Brain Pathol. 2020;30(6):1087–101. https://doi.org/10.1111/bpa.12888.

103.

Sagare AP, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013;4:2932.PubMedCrossRef

104.

Miners JS, Schulz I, Love S. Differing associations between Aβ accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer’s disease. J Cereb Blood Flow Metab. 2018;38(1):103–15.PubMedCrossRef

105.

Verbeek MM, et al. Rapid degeneration of cultured human brain pericytes by amyloid β protein. J Neurochem. 1997;68(3):1135–41.PubMedCrossRef

106.

Rabin JS, et al. Vascular risk and β-amyloid are synergistically associated with cortical tau. Ann Neurol. 2019;85(2):272–9.PubMedPubMedCentralCrossRef

107.

Kim HJ, et al. Assessment of extent and role of tau in subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging. JAMA Neurol. 2018;75(8):999–1007.PubMedPubMedCentralCrossRef

108.

Wen Y, et al. Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res. 2004;1022(1–2):30–8.PubMedCrossRef

109.

Qiu L, et al. Chronic cerebral hypoperfusion enhances tau hyperphosphorylation and reduces autophagy in Alzheimer's disease mice. Sci Rep. 2016;6:23964.PubMedPubMedCentralCrossRef

110.

Burkhart KK, et al. Alterations in tau phosphorylation in rat and human neocortical brain slices following hypoxia and glucose deprivation. Exp Neurol. 1998;154(2):464–72.PubMedCrossRef

111.

Liu CC, Yamazaki Y, Heckman MG, Martens YA, Jia L, Yamazaki A, Diehl NN, Zhao J, Zhao N, DeTure M, Davis MD, Felton LM, Qiao W, Li Y, Li H, Fu Y, Wang N, Wren M, Aikawa T, Holm ML, Oue H, Linares C, Allen M, Carrasquillo MM, Murray ME, Petersen RC, Ertekin-Taner N, Dickson DW, Kanekiyo T, Bu G. Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. Alzheimers Dement. 2020;16(10):1372–83. https://doi.org/10.1002/alz.12104.

112.

Bennett RE, et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer’s disease. Proc Natl Acad Sci U S A. 2018;115(6):E1289–98.PubMedPubMedCentralCrossRef

113.

Park L, et al. Tau induces PSD95-neuronal NOS uncoupling and neurovascular dysfunction independent of neurodegeneration. Nat Neurosci. 2020;23(9):1079–89.PubMedCrossRefPubMedCentral

114.

Bourassa P, et al. Brain mural cell loss in the parietal cortex in Alzheimer’s disease correlates with cognitive decline and TDP-43 pathology. Neuropathol Appl Neurobiol. 2020;46(5):458–77.PubMedCrossRefPubMedCentral

115.

Thammisetty SS, et al. Age-related deregulation of TDP-43 after stroke enhances NF-kappaB-mediated inflammation and neuronal damage. J Neuroinflammation. 2018;15(1):312.PubMedPubMedCentralCrossRef

116.

Swirski M, et al. Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease. Alzheimers Res Ther. 2014;6(5–8):77.PubMedPubMedCentralCrossRef

117.

Pietronigro E, Zenaro E, Constantin G. Imaging of leukocyte trafficking in Alzheimer’s disease. Front Immunol. 2016;7:33.PubMedPubMedCentralCrossRef

118.

Zenaro E, et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21(8):880–6.PubMedCrossRef

119.

McManus RM, et al. Respiratory infection promotes T cell infiltration and amyloid-β deposition in APP/PS1 mice. Neurobiol Aging. 2014;35(1):109–21.PubMedCrossRef

120.

Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80. e8.PubMedPubMedCentralCrossRef

121.

Xu J, Lazartigues E. Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus. Cell Mol Neurobiol. 2020:1–5. https://doi.org/10.1007/s10571-020-00915-1.

122.

Lukiw WJ, Pogue A, Hill JM. SARS-CoV-2 Infectivity and Neurological Targets in the Brain. Cell Mol Neurobiol. 2020:1–8. https://doi.org/10.1007/s10571-020-00947-7.

123.

Netland J, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75.PubMedPubMedCentralCrossRef

124.

Jiang RD, Liu MQ, Chen Y, Shan C, Zhou YW, Shen XR, Li Q, Zhang L, Zhu Y, Si HR, Wang Q, Min J, Wang X, Zhang W, Li B, Zhang HJ, Baric RS, Zhou P, Yang XL, Shi ZL. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. Cell. 2020;182(1):50–8.e8. https://doi.org/10.1016/j.cell.2020.05.027.

125.

Kuba K, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–9.PubMedPubMedCentralCrossRef

126.

Glowacka I, et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol. 2010;84(2):1198–205.PubMedCrossRef

127.

Haga S, et al. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci U S A. 2008;105(22):7809–14.PubMedPubMedCentralCrossRef

128.

Ferreira AJ, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55(2):207–13.PubMedCrossRef

129.

Paz Ocaranza M, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116–29.PubMedCrossRef

130.

Arroja MM, Reid E, McCabe C. Therapeutic potential of the renin angiotensin system in ischaemic stroke. Exp Transl Stroke Med. 2016;8:8.PubMedPubMedCentralCrossRef

131.

Chrysant SG. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens (Greenwich). 2007;9(6):454–9.CrossRef

132.

McCarthy CA, Facey LJ, Widdop RE. The protective arms of the renin-angiontensin system in stroke. Curr Hypertens Rep. 2014;16(7):440.PubMedCrossRef

133.

Evans CE, et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease. Acta Neuropathol. 2020;139(3):485–502.PubMedPubMedCentralCrossRef

134.

Wang XL, et al. Deficiency of angiotensin-converting enzyme 2 causes deterioration of cognitive function. NPJ Aging Mech Dis. 2016;2:16024.PubMedPubMedCentralCrossRef

135.

Lanza K, et al. Covid-19: the renin-angiotensin system imbalance hypothesis. Clin Sci (Lond). 2020;134(11):1259–64.CrossRef

136.

Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14–20. https://doi.org/10.1016/j.ejim.2020.04.037.

137.

Deshotels MR, et al. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014;64(6):1368–75.PubMedCrossRef

138.

Pasanen L, Launonen H, Siltari A, Korpela R, Vapaatalo H, Salmenkari H, Forsgard RA. Age-related changes in the local intestinal renin-angiotensin system in normotensive and spontaneously hypertensive rats. J Physiol Pharmacol. 2019;70(2). https://doi.org/10.26402/jpp.2019.2.03.

139.

Schouten LR, et al. Age-dependent changes in the pulmonary renin-angiotensin system are associated with severity of lung injury in a model of acute lung injury in rats. Crit Care Med. 2016;44(12):e1226–35.PubMedCrossRef

140.

Xie X, et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166–71.PubMedCrossRef

141.

Yoon HE, et al. Age-associated changes in the vascular renin-angiotensin system in mice. Oxid Med Cell Longev. 2016;2016:6731093.PubMedPubMedCentralCrossRef

142.

Bukowska A, et al. Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp Biol Med (Maywood). 2017;242(14):1412–23.CrossRef

143.

Stelzig KE, et al. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1280–1.PubMedPubMedCentralCrossRef

144.

Cao Y, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6:11.PubMedPubMedCentralCrossRef

145.

Li W, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005;24(8):1634–43.PubMedPubMedCentralCrossRef

146.

Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2020:pvaa064. https://doi.org/10.1093/ehjcvp/pvaa064.

147.

Zhang X, et al. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis. Pharmacol Res. 2020;158:104927.PubMedPubMedCentralCrossRef

148.

Wang D, et al. Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation. Pulm Pharmacol Ther. 2019;58:101833.PubMedPubMedCentralCrossRef

149.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. https://doi.org/10.1001/jamainternmed.2020.0994.

150.

Fan E, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med. 2020;8(8):816–21.PubMedPubMedCentralCrossRef

151.

Doerschug KC, et al. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care. 2010;14(1):R24.PubMedPubMedCentralCrossRef

152.

Imai Y, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6.PubMedPubMedCentralCrossRef

153.

Wosten-van Asperen RM, et al. Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome. Pediatr Crit Care Med. 2013;14(9):e438–41.PubMedCrossRef

154.

Crowley SD, Rudemiller NP. Immunologic effects of the renin-angiotensin system. J Am Soc Nephrol. 2017;28(5):1350–61.PubMedPubMedCentralCrossRef

155.

Meng J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–60.PubMedPubMedCentralCrossRef

156.

Rey-Parra GJ, et al. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J Mol Med (Berl). 2012;90(6):637–47.CrossRef

157.

Fang Y, Gao F, Liu Z. Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-kappaB and Nrf2 pathways. QJM. 2019;112(12):914–24.PubMedCrossRef

158.

Klein N, et al. Angiotensin-(1-7) protects from experimental acute lung injury. Crit Care Med. 2013;41(11):e334–43.PubMedCrossRef

159.

Haddad JJ, Saade NE, Safieh-Garabedian B. Interleukin-10 and the regulation of mitogen-activated protein kinases: are these signalling modules targets for the anti-inflammatory action of this cytokine? Cell Signal. 2003;15(3):255–67.PubMedCrossRef

160.

Zoufaly A, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8(11):1154–8.PubMedPubMedCentralCrossRef

161.

Abd El-Aziz, T.M., A. Al-Sabi, and J.D. Stockand, Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19. Signal Transduct Target Ther, 2020. 5(1): p. 258.

162.

Kehoe PG, et al. Angiotensin-III is increased in Alzheimer’s disease in association with amyloid-β and tau pathology. J Alzheimers Dis. 2017;58(1):203–14.PubMedCrossRef

163.

Miners JS, et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2008;34(2):181–93.PubMedCrossRef

164.

Miners S, et al. Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res. 2009;1(2):163–77.PubMedPubMedCentral

165.

Tian M, et al. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett. 2012;586(20):3737–45.PubMedCrossRef

166.

Zhu D, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. Plos One. 2011;6(1):e16037.PubMedPubMedCentralCrossRef

167.

Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer’s disease: progress toward disease prevention and treatment? J Alzheimers Dis. 2018;62(3):1443–66.PubMedPubMedCentralCrossRef

168.

Chen JL, et al. Angiotensin-(1-7) administration attenuates Alzheimer’s disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation. Neuroscience. 2017;346:267–77.PubMedCrossRef

169.

Kamel AS, et al. Stimulation of ACE2/ANG(1-7)/Mas axis by diminazene ameliorates Alzheimer’s disease in the d-galactose-ovariectomized rat model: role of PI3K/Akt pathway. Mol Neurobiol. 2018;55(10):8188–202.PubMedCrossRef

170.

Griendling KK, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74(6):1141–8.PubMedCrossRef

171.

Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52(4):639–72.PubMed

172.

Naveri L, Stromberg C, Saavedra JM. Angiotensin II AT1 receptor mediated contraction of the perfused rat cerebral artery. Neuroreport. 1994;5(17):2278–80.PubMedCrossRef

173.

Matsugi T, Chen Q, Anderson DR. Contractile responses of cultured bovine retinal pericytes to angiotensin II. Arch Ophthalmol. 1997;115(10):1281–5.PubMedCrossRef

174.

Kawamura H, et al. Effects of angiotensin II on the pericyte-containing microvasculature of the rat retina. J Physiol. 2004;561(Pt 3):671–83.PubMedPubMedCentralCrossRef

175.

Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab. 2009;29(3):640–7.PubMedCrossRef

176.

Zhang M, et al. Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience. 2010;171(3):852–8.PubMedCrossRef

177.

Carbajo-Lozoya J, et al. Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell Signal. 2012;24(6):1261–9.PubMedCrossRef

178.

Kim JH, et al. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab. 2009;29(3):621–8.PubMedCrossRef

179.

Tamarat R, et al. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 2002;82(6):747–56.PubMedCrossRef

180.

Kazama K, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95(10):1019–26.PubMedCrossRef

181.

Nishimura Y, et al. The angiotensin AT1 receptor antagonist CV-11974 regulates cerebral blood flow and brain angiotensin AT1 receptor expression. Basic Res Cardiol. 1998;93(Suppl 2):63–8.PubMedCrossRef

182.

Vraamark T, et al. Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation. J Hypertens. 1995;13(7):755–61.PubMedCrossRef

183.

Diem AK, et al. A control mechanism for intra-mural peri-arterial drainage via astrocytes: how neuronal activity could improve waste clearance from the brain. Plos One. 2018;13(10):e0205276.PubMedPubMedCentralCrossRef

184.

Tarasoff-Conway JM, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.PubMedPubMedCentralCrossRef

185.

Greenberg SM, et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30–42.PubMedCrossRef

186.

Munk AS, et al. PDGF-B is required for development of the glymphatic system. Cell Rep. 2019;26(11):2955–69. e3.PubMedPubMedCentralCrossRef

187.

Gundersen GA, et al. Evidence that pericytes regulate aquaporin-4 polarization in mouse cortical astrocytes. Brain Struct Funct. 2014;219(6):2181–6.PubMedCrossRef

188.

Qin Y, et al. Aquaporin changes during diabetic retinopathy in rats are accelerated by systemic hypertension and are linked to the renin-angiotensin system. Invest Ophthalmol Vis Sci. 2012;53(6):3047–53.PubMedCrossRef

189.

Gallagher PE, et al. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol. 2006;290(2):C420–6.PubMedCrossRef

190.

Ramanan VK, Saykin AJ. Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer’s disease, Parkinson’s disease, and related disorders. Am J Neurodegener Dis. 2013;2(3):145–75.PubMedPubMedCentral

191.

Tosto G, Reitz C. Genome-wide association studies in Alzheimer’s disease: a review. Curr Neurol Neurosci Rep. 2013;13(10):381.PubMedPubMedCentralCrossRef

192.

Morgan BP. Complement in the pathogenesis of Alzheimer’s disease. Semin Immunopathol. 2018;40(1):113–24.PubMedCrossRef

193.

Heneka MT, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–8.CrossRefPubMed

194.

Ising C, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669–73.PubMedPubMedCentralCrossRef

195.

Shagdarsuren E, et al. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97(7):716–24.PubMedCrossRef

196.

Zhang C, et al. Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling. Arterioscler Thromb Vasc Biol. 2014;34(6):1240–8.PubMedCrossRef

197.

Zhao M, et al. Angiotensin II stimulates the NLRP3 inflammasome to induce podocyte injury and mitochondrial dysfunction. Kidney Dis (Basel). 2018;4(2):83–94.CrossRef

198.

Risitano AM, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–4.PubMedCrossRef

199.

Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020;92(10):2105–13. https://doi.org/10.1002/jmv.25987.

200.

De Batista PR, et al. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. Plos One. 2014;9(8):e104020.PubMedPubMedCentralCrossRef

201.

Nakashima T, et al. TLR4 is a critical regulator of angiotensin II-induced vascular remodeling: the roles of extracellular SOD and NADPH oxidase. Hypertens Res. 2015;38(10):649–55.PubMedPubMedCentralCrossRef

202.

Dange RB, et al. Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res. 2014;103(1):17–27.PubMedCrossRef

203.

Sheikh BN, et al. Neural metabolic imbalance induced by MOF dysfunction triggers pericyte activation and breakdown of vasculature. Nat Cell Biol. 2020;22(7):828–41.PubMedCrossRef

204.

Toelzer, C., et al., Unexpected free fatty acid binding pocket in the cryo-EM structure of SARS-CoV-2 spike protein. bioRxiv 2020. doi: https://doi.org/10.1101/2020.06.18.158584.

205.

Shen B, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59–72. e15.PubMedPubMedCentralCrossRef

206.

Snowden SG, et al. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: a nontargeted metabolomic study. Plos Med. 2017;14(3):e1002266.PubMedPubMedCentralCrossRef

207.

Labandeira-Garcia JL, et al. Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Front Aging Neurosci. 2017;9:129.PubMedPubMedCentralCrossRef

208.

Biancardi VC, et al. Cross talk between AT1 receptors and toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus. Am J Physiol Heart Circ Physiol. 2016;310(3):H404–15.PubMedCrossRef

209.

Liang B, et al. Angiotensin-(1-7) attenuates angiotensin ii-induced ICAM-1, VCAM-1, and MCP-1 expression via the MAS receptor through suppression of p38 and NF-kappaB pathways in HUVECs. Cell Physiol Biochem. 2015;35(6):2472–82.PubMedCrossRef

210.

Rustenhoven J, et al. Brain pericytes as mediators of neuroinflammation. Trends Pharmacol Sci. 2017;38(3):291–304.PubMedCrossRef

211.

Hellner K, et al. Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell Neurosci. 2005;29(3):427–35.PubMedCrossRef

212.

Gironacci MM, et al. Neuromodulatory role of angiotensin-(1-7) in the central nervous system. Clin Sci (Lond). 2013;125(2):57–65.CrossRef

213.

Bennion DM, et al. Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke. Curr Hypertens Rep. 2015;17(2):3.PubMedPubMedCentralCrossRef

214.

Wright JW, Harding JW. Contributions by the brain renin-angiotensin system to memory, cognition, and Alzheimer's disease. J Alzheimers Dis. 2019;67(2):469–80.PubMedCrossRef

215.

Jiang T, et al. ACE2-Ang-(1-7)-Mas axis in brain: a potential target for prevention and treatment of ischemic stroke. Curr Neuropharmacol. 2013;11(2):209–17.PubMedPubMedCentralCrossRef

216.

Regenhardt RW, Bennion DM, Sumners C. Cerebroprotective action of angiotensin peptides in stroke. Clin Sci (Lond). 2014;126(3):195–205.CrossRef

217.

Uekawa K, et al. Intracerebroventricular infusion of angiotensin-(1-7) ameliorates cognitive impairment and memory dysfunction in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2016;53(1):127–33.PubMedCrossRef

218.

Cao C, et al. Chronic angiotensin 1-7 infusion prevents angiotensin-ii-induced cognitive dysfunction and skeletal muscle injury in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2019;69(1):297–309.PubMedCrossRef

219.

Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400.PubMedCrossRef

220.

Tsai MS, et al. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet. 1994;54(4):643–9.PubMedPubMedCentral

221.

Montagne A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71–6.PubMedPubMedCentralCrossRef

222.

Love S, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis. 2014;3(1):19–32.PubMedPubMedCentral

223.

Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, Melzer D. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 202015;75(11):2231–2. https://doi.org/10.1093/gerona/glaa131.

224.

Yamazaki Y, et al. ApoE (Apolipoprotein E) in brain pericytes regulates endothelial function in an isoform-dependent manner by modulating basement membrane components. Arterioscler Thromb Vasc Biol. 2020;40(1):128–44.PubMedCrossRef

225.

Thambisetty M, et al. APOE ϵ4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol. 2010;67(1):93–8.PubMedPubMedCentralCrossRef

226.

Koizumi K, et al. Apoϵ4 disrupts neurovascular regulation and undermines white matter integrity and cognitive function. Nat Commun. 2018;9(1):3816.PubMedPubMedCentralCrossRef

227.

Kloske CM, Wilcock DM. The important interface between apolipoprotein E and neuroinflammation in Alzheimer’s disease. Front Immunol. 2020;11:754.PubMedPubMedCentralCrossRef

228.

Patel VB, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;66:167–76.PubMedCrossRef

229.

Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45(2):146–69.PubMedPubMedCentralCrossRef

230.

Cui S, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–4.PubMedCrossRef

231.

Klok FA, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.PubMedPubMedCentralCrossRef

232.

Martin K, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–13.PubMedPubMedCentralCrossRef

233.

Thachil J, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.PubMedCrossRef

234.

Aryal MR, et al. Venous thromboembolism in COVID-19: towards an ideal approach to thromboprophylaxis, screening, and treatment. Curr Cardiol Rep. 2020;22(7):52.PubMedPubMedCentralCrossRef

235.

Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–70.PubMedCrossRefPubMedCentral

236.

Hegerova L, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136(6):759–62.PubMedCrossRef

237.

Gucyetmez B, et al. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. Crit Care. 2020;24(1):492.PubMedPubMedCentralCrossRef

238.

Morath C, et al. Plasma exchange in critically ill COVID-19 patients. Crit Care. 2020;24(1):481.PubMedPubMedCentralCrossRef

239.

Fernandez-Ruiz M, et al. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study. J Med Virol. 2020;.

240.

Montesarchio V, Parrela R, Iommelli C, Bianco A, Manzillo E, Fraganza F, Palumbo C, Rea G, Murino P, De Rosa R, Atripaldi L, D'Abbraccio M, Curvietto M, Mallardo D, Celentano E, Grimaldi AM, Palla M, Trojaniello C, Vitale MG, Million-Weaver SL, Ascierto PA. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8(2):e001089. https://doi.org/10.1136/jitc-2020-001089.

241.

Leng Z, et al. Transplantation of ACE2(−) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28.PubMedPubMedCentralCrossRef

242.

Cheng Z, et al. Mesenchymal stem cells attenuate blood-brain barrier leakage after cerebral ischemia in mice. J Neuroinflammation. 2018;15(1):135.PubMedPubMedCentralCrossRef

243.

Chao YX, He BP, Tay SS. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson’s disease. J Neuroimmunol. 2009;216(1–2):39–50.PubMedCrossRef

244.

Tang G, et al. Mesenchymal stem cells maintain blood-brain barrier integrity by inhibiting aquaporin-4 upregulation after cerebral ischemia. Stem Cells. 2014;32(12):3150–62.PubMedCrossRef

245.

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5.PubMedPubMedCentralCrossRef

246.

Horby, P., et al., Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv, 2020. doi: https://doi.org/10.1101/2020.06.22.20137273..

247.

Artigas A, et al. Inhalation therapies in acute respiratory distress syndrome. Ann Transl Med. 2017;5(14):293.PubMedPubMedCentralCrossRef

248.

Ortiz-Diaz E, et al. Emerging pharmacological therapies for prevention and early treatment of acute lung injury. Semin Respir Crit Care Med. 2013;34(4):448–58.PubMedCrossRef

249.

Yamaya M, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155–68.PubMedPubMedCentralCrossRef

250.

Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819–20. https://doi.org/10.1128/AAC.00819-20.

251.

Hadjadj J, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–24.PubMedPubMedCentralCrossRef

252.

Felgenhauer U, Schoen A, Gad HH, Hartmann R, Schaubmar AR, Failing K, Drosten C, Weber F. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem. 2020;295(41):13958–64. https://doi.org/10.1074/jbc.AC120.013788.

253.

Hung IF, et al. Triple combination of interferon β-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–704.PubMedPubMedCentralCrossRef

254.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.PubMedPubMedCentralCrossRef

255.

Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, Manfredini R, Mantovani LG, Manzoli L. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519–24. https://doi.org/10.1136/heartjnl-2020-317336.

256.

Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80(13):1267–92. https://doi.org/10.1007/s40265-020-01367-z.

257.

Alijotas-Reig J, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569.PubMedPubMedCentralCrossRef

258.

Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol. 2020;883:173372. https://doi.org/10.1016/j.ejphar.2020.173372.

259.

Bianchetti A, et al. Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging. 2020;24(6):560–2.PubMedCrossRefPubMedCentral

260.

Hwang JM, et al. Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci. 2020;41(9):2317–24.PubMedCrossRefPubMedCentral

Titel: Cognitive impact of COVID-19: looking beyond the short term
verfasst von: Scott Miners
Patrick G. Kehoe
Seth Love
Publikationsdatum: 01.12.2020
Verlag: BioMed Central
Erschienen in: Alzheimer's Research & Therapy / Ausgabe 1/2020
Elektronische ISSN: 1758-9193
DOI: https://doi.org/10.1186/s13195-020-00744-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Publisher’s Note

Background

Cerebral vascular disease (CVD) is common in severe COVID-19

SARS-CoV-2 infects human brain

The types of cerebral ischaemic damage seen in COVID-19 are major contributors to cognitive decline and dementia

Angiotensin-converting enzyme-2-mediated entry of SARS-CoV-2 into human cells and activation of the classical renin-angiotensin system

Potential neurological consequences of increased classical renin-angiotensin system activation in COVID-19

Is APOE ε4, an established risk factor for AD and vascular dysfunction, also a risk factor for COVID-19?

Potential upregulation of ADAM-17 in COVID-19

Clinical management, clinical trials and possible future targets for therapeutic intervention in COVID-19 patients

Conclusion

Acknowledgements

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Weitere Artikel der Ausgabe 1/2020

Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40

Cognitive training and brain stimulation in prodromal Alzheimer’s disease (AD-Stim)—study protocol for a double-blind randomized controlled phase IIb (monocenter) trial

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease

Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Update Neurologie